PDCD1 and neoplasm: Since recent clinical papers suggested a potential involvement of the gut microbiome in influencing the efficacy of both CTLA-4- and PD-1-targeting checkpoint inhibitors [49,50,51], the authors of these publications collected the fecal specimens to characterize the mechanisms involved in resistance of immunotherapy on rodent tumor models.